Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval
- PDF / 323,979 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 82 Downloads / 172 Views
PUBLISHER CORRECTION
Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development Andrew J. Krentz1 • Gerardo Rodriguez-Araujo1
Published online: 31 January 2018 Ó Springer International Publishing AG, part of Springer Nature 2018
Publisher Correction: Pharm Med https://doi.org/10.1007/s 40290-017-0209-3 The original version of this article unfortunately contained a mistake. Table 1 was presented incorrectly. The corrected Table 1 is given below. Table 1 MACE primary composite endpoints applied in diabetes CVOTs to date Three-point MACE
Four-point MACE
CV death
CV death
Non-fatal myocardial infarction
Non-fatal myocardial infarction
Non-fatal stroke
Non-fatal stroke Hospitalization for unstable angina
MACE major adverse cardiovascular events, CV cardiovascular, CVOTs cardiovascular outcome trials
The original article can be found online at https://doi.org/10.1007/ s40290-017-0209-3. & Andrew J. Krentz [email protected] 1
ProSciento, 855 3rd Avenue Suite 4400, Chula Vista, CA 91911, USA
Data Loading...
